Webster Joan, Osborne Sonya, Rickard Claire M, New Karen
Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Level 2, Building 34, Butterfield Street, Brisbane, Queensland, Australia, 4029.
Cochrane Database Syst Rev. 2015 Aug 14(8):CD007798. doi: 10.1002/14651858.CD007798.pub4.
US Centers for Disease Control guidelines recommend replacement of peripheral intravenous (IV) catheters no more frequently than every 72 to 96 hours. Routine replacement is thought to reduce the risk of phlebitis and bloodstream infection. Catheter insertion is an unpleasant experience for patients and replacement may be unnecessary if the catheter remains functional and there are no signs of inflammation. Costs associated with routine replacement may be considerable. This is an update of a review first published in 2010.
To assess the effects of removing peripheral IV catheters when clinically indicated compared with removing and re-siting the catheter routinely.
For this update the Cochrane Vascular Trials Search Co-ordinator searched the Cochrane Vascular Specialised Register (March 2015) and CENTRAL (2015, Issue 3). We also searched clinical trials registries (April 2015).
Randomised controlled trials that compared routine removal of peripheral IV catheters with removal only when clinically indicated in hospitalised or community dwelling patients receiving continuous or intermittent infusions.
Two review authors independently assessed trial quality and extracted data.
Seven trials with a total of 4895 patients were included in the review. The quality of the evidence was high for most outcomes but was downgraded to moderate for the outcome catheter-related bloodstream infection (CRBSI). The downgrade was due to wide confidence intervals, which created a high level of uncertainty around the effect estimate. CRBSI was assessed in five trials (4806 patients). There was no significant between group difference in the CRBSI rate (clinically-indicated 1/2365; routine change 2/2441). The risk ratio (RR) was 0.61 (95% CI 0.08 to 4.68; P = 0.64). No difference in phlebitis rates was found whether catheters were changed according to clinical indications or routinely (clinically-indicated 186/2365; 3-day change 166/2441; RR 1.14, 95% CI 0.93 to 1.39). This result was unaffected by whether infusion through the catheter was continuous or intermittent. We also analysed the data by number of device days and again no differences between groups were observed (RR 1.03, 95% CI 0.84 to 1.27; P = 0.75). One trial assessed all-cause bloodstream infection. There was no difference in this outcome between the two groups (clinically-indicated 4/1593 (0.02%); routine change 9/1690 (0.05%); P = 0.21). Cannulation costs were lower by approximately AUD 7.00 in the clinically-indicated group (mean difference (MD) -6.96, 95% CI -9.05 to -4.86; P ≤ 0.00001).
AUTHORS' CONCLUSIONS: The review found no evidence to support changing catheters every 72 to 96 hours. Consequently, healthcare organisations may consider changing to a policy whereby catheters are changed only if clinically indicated. This would provide significant cost savings and would spare patients the unnecessary pain of routine re-sites in the absence of clinical indications. To minimise peripheral catheter-related complications, the insertion site should be inspected at each shift change and the catheter removed if signs of inflammation, infiltration, or blockage are present.
美国疾病控制中心的指南建议,外周静脉(IV)导管的更换频率不应超过每72至96小时一次。常规更换被认为可降低静脉炎和血流感染的风险。导管插入对患者来说是一种不愉快的经历,如果导管仍能正常使用且没有炎症迹象,更换可能是不必要的。与常规更换相关的成本可能相当可观。这是2010年首次发表的一篇综述的更新。
评估在临床指征明确时拔除外周IV导管与常规拔除并重新置管相比的效果。
本次更新中,Cochrane血管试验搜索协调员检索了Cochrane血管专业注册库(2015年3月)和CENTRAL(2015年第3期)。我们还检索了临床试验注册库(2015年4月)。
比较住院或社区居住患者接受连续或间歇输液时,外周IV导管常规拔除与仅在临床指征明确时拔除的随机对照试验。
两位综述作者独立评估试验质量并提取数据。
本综述纳入了7项试验,共4895名患者。大多数结局的证据质量较高,但导管相关血流感染(CRBSI)结局的证据质量被降为中等。降级是由于置信区间较宽,这在效应估计周围产生了高度的不确定性。在5项试验(4806名患者)中评估了CRBSI。两组之间的CRBSI发生率无显著差异(临床指征明确组1/2365;常规更换组2/2441)。风险比(RR)为0.61(95%CI为0.08至4.68;P = 0.64)。无论导管是根据临床指征更换还是常规更换,静脉炎发生率均无差异(临床指征明确组186/2365;3天更换组166/